Number of shares and voting rights, as of April 30, 2007
Turnover of 1.5 million euros for the first quarter of 2007
Two additional clinical trials for IPH 1101, including the first Innate's trial outside oncology
Financial results for 2006
Number of shares and voting rights, as of February 28, 2007
New animal model dedicated to studying NK cell activity
IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in humans
Number of shares and voting rights, as of January 31, 2007
Operating revenue of 8.4 million euros in 2006
Operating revenue of 8.4 million euros in 2006
